Black Rock Inc. Lipocine Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.3 - $0.58 $1,904 - $3,681	6,348 Added 0.43%	1,467,420 $469,000
Q4 2022 Feb 13, 2023	BUY	$0.37 - $8.65 $2,262 - $52,886	6,114 Added 0.42%	1,461,072 $584,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $77,437 - $1.21 Million	-158,036 Reduced 9.8%	1,454,958 $655,000
Q2 2022 Aug 12, 2022	BUY	$0.73 - $1.34 $35,260 - $64,724	48,302 Added 3.09%	1,612,994 $1.29 Million
Q1 2022 May 12, 2022	SELL	$0.89 - $1.85 $26,570 - $55,231	-29,855 Reduced 1.87%	1,564,692 $2.14 Million
Q4 2021 Feb 10, 2022	BUY	$0.99 - $1.2 $13,888 - $16,834	14,029 Added 0.89%	1,594,547 $1.58 Million
Q3 2021 Nov 09, 2021	SELL	$1.08 - $1.49 $2,048 - $2,826	-1,897 Reduced 0.12%	1,580,518 $1.72 Million
Q2 2021 Aug 11, 2021	BUY	$1.17 - $1.59 $1.85 Million - $2.52 Million	1,582,415 New	1,582,415 $2.22 Million

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.